Insight 2811 Inc. Sells 2,897 Shares of CVS Health (CVS)

Insight 2811 Inc. lessened its stake in CVS Health (NYSE:CVS) by 23.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,531 shares of the pharmacy operator’s stock after selling 2,897 shares during the quarter. Insight 2811 Inc.’s holdings in CVS Health were worth $691,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Ontario Teachers Pension Plan Board grew its position in CVS Health by 1.4% in the second quarter. Ontario Teachers Pension Plan Board now owns 937,658 shares of the pharmacy operator’s stock worth $75,444,000 after acquiring an additional 13,224 shares during the period. Sun Life Financial INC grew its position in CVS Health by 17,000.0% in the second quarter. Sun Life Financial INC now owns 7,353 shares of the pharmacy operator’s stock worth $592,000 after acquiring an additional 7,310 shares during the period. Meridian Investment Counsel Inc. grew its position in CVS Health by 12.5% in the second quarter. Meridian Investment Counsel Inc. now owns 12,155 shares of the pharmacy operator’s stock worth $978,000 after acquiring an additional 1,350 shares during the period. QCM Cayman Ltd. grew its position in CVS Health by 147.6% in the second quarter. QCM Cayman Ltd. now owns 11,172 shares of the pharmacy operator’s stock worth $899,000 after acquiring an additional 6,659 shares during the period. Finally, Optimum Investment Advisors grew its position in CVS Health by 20.0% in the second quarter. Optimum Investment Advisors now owns 3,444 shares of the pharmacy operator’s stock worth $277,000 after acquiring an additional 573 shares during the period. 83.97% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

In related news, EVP Helena Foulkes sold 19,965 shares of CVS Health stock in a transaction on Friday, February 16th. The stock was sold at an average price of $71.04, for a total value of $1,418,313.60. Following the completion of the transaction, the executive vice president now directly owns 65,072 shares in the company, valued at $4,622,714.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.61% of the company’s stock.

NYSE:CVS opened at $66.10 on Tuesday. The firm has a market capitalization of $64,351.77, a P/E ratio of 11.20, a P/E/G ratio of 1.05 and a beta of 1.05. CVS Health has a 12-month low of $60.14 and a 12-month high of $84.00. The company has a quick ratio of 0.52, a current ratio of 1.02 and a debt-to-equity ratio of 0.59.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.88 by $0.04. The firm had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. CVS Health’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the business posted $1.71 earnings per share. equities research analysts predict that CVS Health will post 6.3 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 3rd. Investors of record on Monday, April 23rd will be issued a $0.50 dividend. The ex-dividend date is Friday, April 20th. This represents a $2.00 dividend on an annualized basis and a yield of 3.03%. CVS Health’s dividend payout ratio (DPR) is presently 33.90%.

Several research firms have recently commented on CVS. Needham & Company LLC set a $98.00 price target on CVS Health and gave the stock a “buy” rating in a research report on Friday, February 9th. ValuEngine lowered CVS Health from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Leerink Swann set a $85.00 price target on CVS Health and gave the stock a “buy” rating in a research report on Friday, February 9th. Vetr lowered CVS Health from a “hold” rating to a “sell” rating and set a $76.66 price target for the company. in a research report on Tuesday, January 16th. Finally, Citigroup set a $77.00 price target on CVS Health and gave the stock a “neutral” rating in a research report on Tuesday, February 13th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $86.65.

ILLEGAL ACTIVITY NOTICE: “Insight 2811 Inc. Sells 2,897 Shares of CVS Health (CVS)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/17/insight-2811-inc-sells-2897-shares-of-cvs-health-cvs.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply